Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Am J Physiol Lung Cell Mol Physiol
2016 Aug 01;3112:L192-207. doi: 10.1152/ajplung.00056.2016.
Show Gene links
Show Anatomy links
Potentiators exert distinct effects on human, murine, and Xenopus CFTR.
Cui G, Khazanov N, Stauffer BB, Infield DT, Imhoff BR, Senderowitz H, McCarty NA.
???displayArticle.abstract???
VX-770 (Ivacaftor) has been approved for clinical usage in cystic fibrosis patients with several CFTR mutations. Yet the binding site(s) on CFTR for this compound and other small molecule potentiators are unknown. We hypothesize that insight into this question could be gained by comparing the effect of potentiators on CFTR channels from different origins, e.g., human, mouse, and Xenopus (frog). In the present study, we combined this comparative molecular pharmacology approach with that of computer-aided drug discovery to identify and characterize new potentiators of CFTR and to explore possible mechanism of action. Our results demonstrate that 1) VX-770, NPPB, GlyH-101, P1, P2, and P3 all exhibited ortholog-specific behavior in that they potentiated hCFTR, mCFTR, and xCFTR with different efficacies; 2) P1, P2, and P3 potentiated hCFTR in excised macropatches in a manner dependent on the degree of PKA-mediated stimulation; 3) P1 and P2 did not have additive effects, suggesting that these compounds might share binding sites. Also 4) using a pharmacophore modeling approach, we identified three new potentiators (IOWH-032, OSSK-2, and OSSK-3) that have structures similar to GlyH-101 and that also exhibit ortholog-specific potentiation of CFTR. These could potentially serve as lead compounds for development of new drugs for the treatment of cystic fibrosis. The ortholog-specific behavior of these compounds suggest that a comparative pharmacology approach, using cross-ortholog chimeras, may be useful for identification of binding sites on human CFTR.
Ai,
Capsaicin potentiates wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride-channel currents.
2004,
Pubmed Alexander,
Cystic fibrosis transmembrane conductance regulator: using differential reactivity toward channel-permeant and channel-impermeant thiol-reactive probes to test a molecular model for the pore.
2009,
Pubmed
,
Xenbase Ataullakhanov,
What determines the intracellular ATP concentration.
2002,
Pubmed Beis,
The contents of adenine nucleotides, phosphagens and some glycolytic intermediates in resting muscles from vertebrates and invertebrates.
1975,
Pubmed Berger,
Curcumin stimulates cystic fibrosis transmembrane conductance regulator Cl- channel activity.
2005,
Pubmed Bose,
Exploiting species differences to understand the CFTR Cl- channel.
2015,
Pubmed Caldwell,
Increased folding and channel activity of a rare cystic fibrosis mutant with CFTR modulators.
2011,
Pubmed Caputo,
Mutation-specific potency and efficacy of cystic fibrosis transmembrane conductance regulator chloride channel potentiators.
2009,
Pubmed Csanády,
Structure-activity analysis of a CFTR channel potentiator: Distinct molecular parts underlie dual gating effects.
2014,
Pubmed
,
Xenbase Cui,
Differential contribution of TM6 and TM12 to the pore of CFTR identified by three sulfonylurea-based blockers.
2012,
Pubmed
,
Xenbase Cui,
Murine and human CFTR exhibit different sensitivities to CFTR potentiators.
2015,
Pubmed
,
Xenbase Cui,
Two salt bridges differentially contribute to the maintenance of cystic fibrosis transmembrane conductance regulator (CFTR) channel function.
2013,
Pubmed
,
Xenbase Cui,
Three charged amino acids in extracellular loop 1 are involved in maintaining the outer pore architecture of CFTR.
2014,
Pubmed
,
Xenbase Dong,
Human-mouse cystic fibrosis transmembrane conductance regulator (CFTR) chimeras identify regions that partially rescue CFTR-ΔF508 processing and alter its gating defect.
2012,
Pubmed Drumm,
Chloride conductance expressed by delta F508 and other mutant CFTRs in Xenopus oocytes.
1991,
Pubmed
,
Xenbase Duret,
Functional prokaryotic-eukaryotic chimera from the pentameric ligand-gated ion channel family.
2011,
Pubmed
,
Xenbase Irwin,
ZINC--a free database of commercially available compounds for virtual screening.
2005,
Pubmed Irwin,
ZINC: a free tool to discover chemistry for biology.
2012,
Pubmed Jones,
Lumacaftor/ivacaftor for patients homozygous for Phe508del-CFTR: should we curb our enthusiasm?
2015,
Pubmed Liu,
Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ΔF508 CFTR from thermal instability.
2014,
Pubmed
,
Xenbase Mandal,
Rational drug design.
2009,
Pubmed McCarty,
Identification of a region of strong discrimination in the pore of CFTR.
2001,
Pubmed
,
Xenbase Melani,
Modulation of cystic fibrosis transmembrane conductance regulator (CFTR) activity and genistein binding by cytosolic pH.
2010,
Pubmed Mense,
In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer.
2006,
Pubmed
,
Xenbase Moran,
A quantitative description of the activation and inhibition of CFTR by potentiators: Genistein.
2005,
Pubmed Muanprasat,
Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy.
2004,
Pubmed Namkung,
Novel amino-carbonitrile-pyrazole identified in a small molecule screen activates wild-type and ΔF508 cystic fibrosis transmembrane conductance regulator in the absence of a cAMP agonist.
2013,
Pubmed Pedemonte,
Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating.
2005,
Pubmed Phuan,
Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis.
2011,
Pubmed Price,
Function of Xenopus cystic fibrosis transmembrane conductance regulator (CFTR) Cl channels and use of human-Xenopus chimeras to investigate the pore properties of CFTR.
1996,
Pubmed
,
Xenbase Rahman,
Modeling the conformational changes underlying channel opening in CFTR.
2013,
Pubmed Ramsey,
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.
2011,
Pubmed Scott-Ward,
Chimeric constructs endow the human CFTR Cl- channel with the gating behavior of murine CFTR.
2007,
Pubmed Thiagarajah,
CFTR inhibitors for treating diarrheal disease.
2012,
Pubmed Tucker,
Identification and developmental expression of the Xenopus laevis cystic fibrosis transmembrane conductance regulator gene.
1992,
Pubmed
,
Xenbase Uhler,
Cellular concentrations of protein kinase A modulate prostaglandin and cAMP induction of alkaline phosphatase.
1992,
Pubmed Van Goor,
Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function.
2014,
Pubmed Van Goor,
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.
2009,
Pubmed Van Goor,
Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules.
2006,
Pubmed Veit,
Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.
2014,
Pubmed Wainwright,
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
2015,
Pubmed Walters,
Mechanism by which calcium phosphate coprecipitation enhances adenovirus-mediated gene transfer.
1999,
Pubmed Wang,
Activating cystic fibrosis transmembrane conductance regulator channels with pore blocker analogs.
2005,
Pubmed Wang,
Robust Stimulation of W1282X-CFTR Channel Activity by a Combination of Allosteric Modulators.
2016,
Pubmed Wolber,
LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters.
2005,
Pubmed Yu,
Identification of a lipid scrambling domain in ANO6/TMEM16F.
2015,
Pubmed Zhang,
Direct comparison of NPPB and DPC as probes of CFTR expressed in Xenopus oocytes.
2000,
Pubmed
,
Xenbase
